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Abstract
Chk2 is an effector kinase important for the activation of cell cycle checkpoints, p53, and apoptosis in response to DNA
damage. Mus81 is required for the restart of stalled replication forks and for genomic integrity. Mus81
Dex3-4/Dex3-4 mice have
increased cancer susceptibility that is exacerbated by p53 inactivation. In this study, we demonstrate that Chk2 inactivation
impairs the development of Mus81
Dex3-4/Dex3-4 lymphoid cells in a cell-autonomous manner. Importantly, in contrast to its
predicted tumor suppressor function, loss of Chk2 promotes mitotic catastrophe and cell death, and it results in suppressed
oncogenictransformation and tumordevelopment inMus81
Dex3-4/Dex3-4 background. Thus, ourdata indicate thatan important
role for Chk2 is maintaining lymphocyte development and that dual inactivation of Chk2 and Mus81 remarkably inhibits
cancer.
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Introduction
DNA damage response is a result of the coordinated actions of
DNA damage signaling and repair pathways, cell cycle check-
points, and apoptosis [1]. Highlighting the importance of the
damage signaling and repair mechanisms, mutations of genes such
as ATM, BRCA1 and NBS1, involved in these mechanisms, are
associated with increased DNA damage sensitivity, genomic
instability, cancer predisposition, immunodeficiency, and devel-
opmental defects [2].
Mammalian Mus81 with its partners Eme1 or Eme2 form a
heterodimeric structure-specific endonuclease that preferentially
cleaves 39 Flaps and replication fork intermediates [3]. This
endonuclease has been shown to facilitate restart of stalled DNA
replication forks by generating DNA double-strand breaks (DSBs)
[4]. Mus81 also interacts with other DNA damage repair proteins
including Rad54, Blm, as well as SLX4 [5–7]. Interestingly, Cds1,
the yeast homolog of the mammalian Serine/Threonine kinase
Chk2, was reported to phosphorylate and release mus81 from
chromatin, presumably to prevent it from cleaving stalled
replication forks (RFs) [8].
Three strains of Mus81 mutant mice have been reported. In
addition to Mus81 inactivation, Mus81
Dex1-10 mice have been
reported to also display decreased expression of Fibulin-4 gene.
Several of these homozygous mutant mice developed cardiovas-
cular complications and died before reaching weaning age [9].
The phenotypes of these mice have been attributed to the
decreased expression of Fibulin-4 [9]. Mus81
Dex9-12 mice have been
also reported [10]. These mice displayed increased sensitivity to
interstrand crosslinking (ICL) agents including MMC. Genomic
instability was reported to be increased in homozygous Mus81
Dex9-12
MEFs expressing the human papillomavirus type 16 E6 that
promotes degradation of p53. While these mutant mice were viable,
they showed no increased of tumorigenesis when monitored for a
period of 15 months [10]. The Mus81
Dex3-4 mutant mice and cells
that we have generated were also highly sensitive to MMC [11].
Mice homozygous for the Mus81
Dex3-4 mutation showed no
expression of Mus81 protein, and displayed elevated levels of
spontaneous genomic instability and cancer predisposition [11].
While thecause forthelackoftumorigenesis in Mus81
Dex9-12 mutant
mice is still not clear, inactivation of p53 in Mus81
Dex3-4/Dex3-4 mice
rescued their MMC hypersensitivity and exacerbated their genomic
instability and tumorigenesis [12].
Inactivation of MUS81 in human cells also resulted in
hypersensitivity to ICL agents and elevated levels of geno-
mic instability[13]. Importantly, MUS81 expression was found
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this reduced expression correlates with a poor prognosis for
patients with this cancer [14]. Moreover, a variant MUS81 allele
(rs545500) was recently associated with increased risk for breast
cancer [15].
CHK2 plays important roles in the DNA damage response, the
signaling of the ATM-CHK2-P53 pathway and in cell cycle
checkpoints including G2/M checkpoint [16,17]. CHK2 phos-
phorylates a number of substrates including p53, CDC25A,
CDC25C, BRCA1, E2F1, and MDC1. A role for CHK2 in cancer
is supported by its rare germline or somatic mutations in certain
humanfamilialcancersand ina numberoftumorsandbyitscentral
role in oncogene-induced senescence [18,19]. Interestingly, mount-
ing evidence also supports the benefit of CHK2 inhibition in
promoting tumor killing in response to genotoxic drugs [16].
Given the importance of Chk2 and Mus81 in DNA damage
signaling and repair respectively, we have examined the effect of
their dual inactivation on lymphoid cell differentiation, DNA
damage response and cancer.
Results/Discussion
Chk2 Deficiency Does Not Affect Embryonic
Development of Mus81
Dex3-4/Dex3-4 Mice
In contrast to the female specific embryonic lethality of
Mus81
Dex3-4/Dex3-4 mice in p53 deficient background [12],
Mus81
Dex3-4/Dex3-4Chk2
2/2 mice were viable and born at the
expected Mendelian ratio (Table S1). We next examined the
fertility of Mus81
Dex3-4/Dex3-4Chk2
2/2 mice and have also further
assessed the viability of double mutant females. Interbreeding of
Mus81
Dex3-4/Dex3-4Chk2
2/2 mice as well as their breeding (males
and females) to mice from different genotypes resulted in normal
size litters compared to control mice (P,0.05; Table S1). In
addition, interbreeding of double mutant mice or heterozygous
compound mice resulted in the expected ratio of males and
females (P,0.05; Table S2). Double mutant males and females
were indistinguishable from their wildtype (WT) and single mutant
littermates. Examination of the weight of 6 to 8 week old and 4 to
8 month old double mutant males and females indicated no
significant differences compared to WT mice and single mutant
controls (Figure S1A).
Collectively, these data indicate that Mus81
Dex3-4/Dex3-4Chk2
2/2
males and females were viable and fertile, and their gross
morphology was indistinguishable from their WT and single
mutant littermates.
Requirement of Chk2 and Mus81 for Homeostasis of
Peripheral T and B-Cells
DNA damage signaling and repair are essential for the
development and function of the immune system and their failure
impairs hematopoietic cell differentiation [20]. We therefore
examined the effect of inactivation of Chk2 on the development
and homeostasis of the lymphocytes of Mus81
Dex3-4/Dex3-4
mice. FACS analysis of splenocytes from 6 to 8 week old
Mus81
Dex3-4/Dex3-4Chk2
2/2 mice showed significant impairment of
the ratio of T-cells (Thy1.2
+) to B-cells (B220
+) (Figure 1A and
Figure S2A). The absolute number of splenocytes was significantly
decreased in double mutant mice (40.9610
662.1) compared to
Mus81
Dex3-4/Dex3-4 (68.4610
663.6; P=0.0002), Chk2
2/2 (73.96
10
663.7; P,0.0001) and WT (74.9610
662.7; P,0.0001) litter-
mates (Figure 1B). The absolute number of B-cells was also
significantly reduced in spleen of double mutant mice
(12.4610
660.6) compared to Mus81
Dex3-4/Dex3-4 (32.8610
661.7;
P,0.0001), Chk2
2/2 (46610
662.3; P,0.0001) and WT
(44.561.6; P,0.0001) mice (Figure 1C). The absolute number
of T-cells in the spleen of double mutant mice (15.9610
660.8) was
also significantly decreased compared to Mus81
Dex3-4/Dex3-4
(21610
661.1; P=0.007), Chk2
2/2 (19.4610
660.3; P=0.02)
and WT (19.7610
660.7; P=0.01) mice (Figure 1C). Impaired
T-cell lineage homeostasis in the absence of Chk2 and Mus81 was
also reflected by the significantly reduced ratio of helper (CD4
+)t o
cytotoxic (CD8
+) T-cells in the spleen of double mutant mice
(1.160.1) compared to Mus81
Dex3-4/Dex3-4 (1.660.1; P=0.028),
Chk2
2/2 (1.960.3; P=0.03) and WT (260.2; P=0.008) mice
(Figure 1A and 1D).
To examine the impaired homeostasis of peripheral lympho-
cytes and the imbalance of the ratio CD4
+ to CD8
+ peripheral T-
cells in double mutant mice, we examined the level of spontaneous
and activation induced death of these cells. Spontaneous cell death
was found significantly increased in both CD4
+ and CD8
+ naı ¨ve
splenocytes from double mutant mice compared to controls
(Figure S3A and S3B). In addition, LPS activation of double
mutant B-cells also resulted in elevated levels of cell death
compared to B-cells from single mutants or WT mice (Figure S7C).
While the number of T-cells and B-cells were reduced in spleen of
double mutant mice, the number of macrophages in these spleens
remained similar to single mutants and WT controls.
Taken together these data demonstrate a specific role for Chk2
in maintaining homeostasis of peripheral T- and B-cells deficient
for Mus81.
Chk2 Loss Affects the Development of Mus81
Dex3-4/Dex3-4
Thymocytes
We next assessed the effect of dual inactivation of Chk2 and
Mus81 on thymocyte development. Similar to peripheral T-cells,
FACS analysis indicated a significantly decreased ratio of CD4
+ to
CD8
+ thymocytes in Mus81
Dex3-4/Dex3-4Chk2
2/2 mice compared to
controls (Figure 1E and 1F). Moreover, total number of
thymocytes was significantly reduced in double mutant mice
(86.3610
665.5) compared to Mus81
Dex3-4/Dex3-4 (121.1610
664.1;
P=0.002), Chk2
2/2 (109.3610
663.9; P=0.015) and WT
(130.9610
668.7; P=0.005) mice (Figure 1G).
Author Summary
Failure to repair DNA damage has been associated with a
number of human syndromes, neurodegenerative diseas-
es, immunodeficiency, and cancer. In addition, radiother-
apy and many cancer chemotherapeutic drugs induce
DNA damage, thus allowing the killing of tumors. Recent
data indicated Mus81’s role in maintaining genomic
integrity and suppressing cancer. Furthermore, inactiva-
tion of p53, the most frequently inactivated tumor
suppressor in cancer, leads to synergistic tumorigenesis
in Mus81 mutant mice. As Chk2 is important for p53
activation, we have examined the effect of its inactivation
on the phenotypes associated with Mus81 loss of function.
We report that Chk2 is essential for the development of
lymphoid cells deficient for Mus81. Chk2 inactivation
increased spontaneous cell death of Mus81 deficient cells
and impaired the development of T and B-cell lineages.
Chk2 inactivation also reduced the frequency of Mus81-
deficient cells that carry elevated levels of spontaneous
genomic instability. Importantly, inactivation of Chk2
protected Mus81 mutant mice from developing spontane-
ous tumorigenesis. These data indicate potential thera-
peutic benefits for the inactivation of Chk2 and Mus81.
Inactivation of Chk2 and Mus81 Suppresses Cancer
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2CD8
2) thymocytes
and their subpopulations DNI (CD44
+CD25
2), DNII
(CD44
+CD25
+), DNIII (CD44
2CD25
+) and DNIV
(CD44
2CD25
2) from double mutant mice, single mutants and
controls indicated no significant differences in cell numbers
(P.0.05; Figure S2C). However, the numbers of CD4
+CD8
+
and CD4
+ thymocytes from Mus81
Dex3-4/Dex3-4Chk2
2/2 mice were
significantly reduced compared to control littermates (Figure S2D
and S2E).
We next examined the level of expression of TCRb expression in
thymocytes from the four genotypes using FACS analysis and anti-
pan TCRb chain constant region, anti-TCRVb4, anti-TCRVb5
and anti-TCRVb17a. Consistent with the normal number of
CD4
2CD8
2 thymocyte population in Mus81
Dex3-4/Dex3-4Chk2
2/2
mice, double mutant thymocytes displayed no significant difference
in the level of TCRb expression or in the percentages of thymocytes
expressing these TCRVb compared to controls (Figure S4A and
S4B). Consistent with these data, no difference was observed in
TCRb expression between Mus81
Dex3-4/Dex3-4Chk2
2/2 and control
splenocytes (Figure S4C).
These data indicate no significant changes in TCRVb repertoire
in Mus81
Dex3-4/Dex3-4Chk2
2/2 mice compared to controls. There-
fore, we conclude that inactivation of Chk2 and Mus81 did not
affect TCR V(D)J recombination. Our data also indicate that while
double negative thymocytes were not affected in Mus81
Dex3-4/Dex3-4
Chk2
2/2 mice, the numbers of double positive and CD4
+
thymocytes were significantly reduced. Therefore, dual inactivation
of Chk2 and Mus81 impairs thymocyte development post DN stage
and this defect likely contributes to the homeostatic imbalance of
peripheral T-cells in Mus81
Dex3-4/Dex3-4Chk2
2/2 mice.
Chk2 Is Required to Maintain the Pool of B-Cell
Precursors in Mus81
Dex3-4/Dex3-4 Mice
To determine whether the observed reduced number of
B-cells in spleen of Mus81
Dex3-4/Dex3-4Chk2
2/2 mice could result
from their impaired differentiation, we examined bone marrow
(BM) cell populations from double mutants and their litter
mate controls. Total number of BM cells was significantly
reduced in double mutant mice (8.7610
661.6) compared to
Mus81
Dex3-4/Dex3-4 (14.4610
661; P=0.012), Chk2
2/2 (14.16
10
660.7; P=0.005) and WT (15.8610
661.3; P=0.012) litter-
mates (Figure 2A). Consistent with the decreased number of
peripheral B-cells in Mus81
Dex3-4/Dex3-4Chk2
2/2 mice, FACS
analysis using antibodies against CD43, B220, IgM and IgD
indicated a significantly reduced representation of mature
recirculating (B220
highCD43
2IgM
+,I g D
+) B-cells in the BM of
double mutant mice compared to controls (P,0.001; Figure 2B
and 2C and Figure S5). Similarly, a significantly reduced
representation of the pro-B (CD43
+B220
+IgM
2) and pre-B
(CD43
2B220
+IgM
2) cells was also observed in Mus81
Dex3-4/Dex3-4
Chk2
2/2 mice (Figure 2B and Figure S5). Examination of
absolute numbers of the pro-B, pre-B and mature B-cell
populations indicated their significant decrease in double mutant
mice (pro-B, P=0.014; pre-B, P=0.003; mature B-cells,
P=0.0001) compared to control littermates (Figure 2C).
To further evaluate the cause for the depletion of BM cells in
the absence of Mus81 and Chk2 we examined the cell death level
of B220
+ BM cells from double mutant mice and control
littermates using Propidium Iodide (PI) staining and FACS
analysis. Remarkably, the level of spontaneous cell death of
B220
+ BM cells was significantly higher in Mus81
Dex3-4/Dex3-4
Chk2
2/2 mice compared to single mutants (P,0.05), and WT
(P,0.01) controls (Figure 2D).
These data indicate that in contrast to the inactivation of either
Mus81 or Chk2, their dual inactivation significantly reduces the
pool of B-cell precursors. Our data also identify increased cell
death as likely to contribute to the defective differentiation of B-
cell lineage in Mus81
Dex3-4/Dex3-4Chk2
2/2 mice. The earlier
differentiation defect of the B-cell lineage compared to T-cell
lineage of Mus81
Dex3-4/Dex3-4Chk2
2/2 mice is likely to contribute to
the more pronounced imbalance of the ratio B- to T-cells in the
periphery of these mice.
Defects in the T and B-Cell Lineages of Mus81
Dex3-4/Dex3-4
Chk2
2/2 Mice Are Cell Autonomous
In order to address whether the phenotypes observed in
Mus81
Dex3-4/Dex3-4Chk2
2/2 mice were cell autonomous or nonau-
tonomous, we have transplanted BM cells from the 4 genotypes
into Rag1
2/2 mice, and have examined the reconstituted mice for
the number and differentiation status of BM cells, thymocytes and
splenocytes (Figure S6). Rag1
2/2 mice arrest their B-cell develo-
pment at the Pro-B stage [21]. Examination of the number of BM
cells in the Rag1
2/2 mice reconstituted with Mus81
Dex3-4/Dex3-4
Chk2
2/2 BM cells indicated no significant differences at the
Pre-B-stage (Figure S6A). However, similar to Mus81
Dex3-4/Dex3-4
Chk2
2/2 mice, reconstituted Rag1
2/2 mice with Mus81
Dex3-4/Dex3-4
Chk2
2/2 BM cells also displayed significantly reduced number of
recirculating B-cells compared to reconstituted controls (P,0.006;
Figure S6B).
Rag1
2/2 mice reconstituted with Mus81
Dex3-4/Dex3-4Chk2
2/2
BM cells, similar to double mutant mice, displayed reduced
number of thymocytes (P,0.03; Figure S6C). In addition, spleen
from these mice also displayed reduced number of total
splenocytes, B-cells, T-cells, CD4
+ T-cells and CD8
+ T-cells
(P,0.05; Figure S6D).
These data indicate that the phenotypes observed with BM,
thymus and spleen of Mus81
Dex3-4/Dex3-4Chk2
2/2 mice were largely
cell autonomous.
Chk2 Inactivation Does Not Rescue MMC Hypersensitivity
of Mus81
Dex3-4/Dex3-4 T-Cells
Hypersensitivity to ICL agents including MMC was reported
for Mus81
Dex1-10 [4], Mus81
Dex9-12 [10] as well as with Mus81
Dex3-4
mutations [11]. The hypersensitivity of Mus81
Dex3-4/Dex3-4 cells was
rescued in p53 null background [12]. Examination of the
proliferation of activated T-cells (anti-CD3 + IL2) using the
Carboxyl fluoroscein succinimidyl ester (CFSE) assay indicated
similar level of cell divisions in T-cells from Mus81
Dex3-4/Dex3-4
Chk2
2/2 mice and control mice (Figure 3A). However, 72 hours
(hr) post-MMC treatment (0.1 mg/ml), double mutant cells
Figure 1. Chk2 Inactivation Impairs Differentiation and Homeostasis of Mus81
2/2 T and B-Cell Lineages. (A) Representative FACS
analysis of total (top panel) and Thy1.2
+ (lower panel) splenocytes from WT, Mus81
Dex3-4/Dex3-4, Chk2
2/2, and Mus81
Dex3-4/Dex3-4Chk2
2/2 mice. (B and C)
Number of splenocytes (B), B-cells (C, left panel) and T-cells (C, right panel) in spleen of Mus81
Dex3-4/Dex3-4Chk2
2/2 mice and controls. (D) Ratio of CD4
+
to CD8
+ T-cells in spleen of Mus81
Dex3-4/Dex3-4Chk2
2/2 mice and controls. (E) Representative FACS analysis of thymocytes from Mus81
Dex3-4/Dex3-4Chk2
2/2
mice and controls. (F and G) Ratio of CD4
+ to CD8
+ thymocytes (F) and number of thymocytes (G) from each strain. At least four independent
experiments using one mouse per group were performed. Percentages of the populations in A and E are indicated. Bar graphs show means 6 SEM.
*, P,0.02; **, P,0.0001. Mus81
2/2: Mus81
Dex3-4/Dex3-4.
doi:10.1371/journal.pgen.1001385.g001
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level observed for Mus81
Dex3-4/Dex3-4 cells (Figure 3A). Moreover,
loss of Chk2 also failed to rescue MMC induced G2 arrest and
apoptosis of Mus81
Dex3-4/Dex3-4 T-cells (Figure 3B and Figure S7A).
We also examined the effect of Mus81 inactivation on the
radioresistance of Chk2
2/2 activated T-cells. A nearly equivalent
resistance was observed in both Mus81
Dex3-4/Dex3-4Chk2
2/2 and
Chk2
2/2 cells 12 hr post ionizing radiation (IR; 4Gy) (Figure S7B),
supporting that Mus81 inactivation has no effect on the
radioresistant phenotype of Chk2
2/2 cells.
Therefore, in contrast to p53 inactivation [12], inactivation of
Chk2 failed to rescue MMC hypersensitivity of Mus81
Dex3-4/Dex3-4
T-cells.
Effect of Chk2 Inactivation on MMC Hypersensitivity of
Mus81
Dex3-4/Dex3-4 BM Cells and Mice
To examine whether Chk2 plays a role in the MMC
hypersensitivity of Mus81
Dex3-4/Dex3-4 BM cells [12], we performed
colony forming assay, in the absence or presence of MMC (40 ng/
ml), using double mutant, Mus81
Dex3-4/Dex3-4, Chk2
2/2 and WT
BM cells. Twelve days post plating, MMC treated BM cells from
Chk2
2/2 and WT mice formed a similar number of colonies
(Figure 3C and 3D). However, similarly to Mus81
Dex3-4/Dex3-4 BM
cells, double mutant BM cells displayed reduced colony-forming
capacity post-MMC treatment (Figure 3C and 3D). Therefore,
inactivation of Chk2 in Mus81
Dex3-4/Dex3-4 BM cells does not rescue
their MMC hypersensitivity.
Given the high in vivo MMC sensitivity of Mus81
Dex3-4/Dex3-4
mice [11] and Mus81
Dex9-12 mice [10], we assessed the effect of
Chk2 inactivation on the MMC hypersensitivity of Mus81 mutant
mice. Cohorts of mice from the four genotypes received
intraperitoneal (i.p) injection of MMC (12.5 mg/kg) and were
monitored for survival (Figure 3E). In contrast to the results of the
in vitro BM colony forming assay suggestive of equivalent MMC
sensitivity of double mutant and Mus81
Dex3-4/Dex3-4 BM cells,
double mutant mice displayed significantly higher sensitivity to
MMC (mean survival =6 days) than Mus81
Dex3-4/Dex3-4 mice
(mean survival =9 days).
As BM failure might contribute to the elevated MMC sensitivity
of Mus81
Dex3-4/Dex3-4Chk2
2/2 mice, we examined the in vivo effects
Figure 2. Impaired Differentiation and Increased Death of Mus81
2/2 B-Cells in the Absence of Chk2. (A and B) Number (A) and
representative FACS analysis (B) of BM cells from WT, Mus81
Dex3-4/Dex3-4, Chk2
2/2, and Mus81
Dex3-4/Dex3-4Chk2
2/2 mice. Percentages of B220
+CD43
+,
B220
+CD43
2 and B220
highCD43
2 cells are indicated. (C and D) Number of pro-B (B220
+CD43
+IgM
2), pre-B (B220
+CD43
2IgM
2)a n d
B220
highCD43
2IgM
+ BM cells (C) and level of spontaneous cell death of the B220
+ BM cells (D) from Mus81
Dex3-4/Dex3-4Chk2
2/2 mice and controls.
Cell death was assessed using PI staining. At least four independent experiments using one mouse per group were performed. Bar graphs show
means 6 SEM. *, P,0.05; **, P,0.005. Mus81
2/2: Mus81
Dex3-4/Dex3-4.
doi:10.1371/journal.pgen.1001385.g002
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2/2 Cells and Mice. (A) Representative CFSE staining of WT,
Mus81
Dex3-4/Dex3-4, Chk2
2/2, and Mus81
Dex3-4/Dex3-4Chk2
2/2 activated T-cells (anti-CD3 + IL2) 120hr post CFSE labelling. Cells were either untreated (UT)
or treated with MMC (0.1 mg/ml) for the last 72 hr (MMC). Percentage of cells achieving two cell divisions is shown. (B) Representative FACS analysis
showing the level of cell death (7AAD
+) of activated T-cells either untreated (UT) or 48 hr post MMC (0.5 mg/ml) treatment. Percent of dead cells is
shown. (C and D) BM colony forming assay. BM cells were plated on media containing 0 or 40 ng/ml of MMC and colonies were counted 10 days
post-treatment. Representative picture of colonies at day 10 of MMC treatment is shown (C). Data normalized to untreated cells is presented as the
mean 6 SD of three independent experiments (D). No statistical significance: ns. (E) Kaplan-Meier survival curve of WT, Mus81
Dex3-4/Dex3-4, Chk2
2/2,
and Mus81
Dex3-4/Dex3-4Chk2
2/2 cohort of mice (n=10 each) in response to i.p injection of MMC (12.5 mg/kg). (F) Representative FACS analysis of cell
death using PI staining and B220 gated BM cells from Mus81
Dex3-4/Dex3-4Chk2
2/2 mice and controls. Mice were either untreated (UT) or received MMC
(12.5 mg/kg) injection three days prior to analysis (MMC). Data shown is representative of at least three independent experiments. Mus81
2/2:
Mus81
Dex3-4/Dex3-4.
doi:10.1371/journal.pgen.1001385.g003
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Dex3-4/Dex3-4Chk2
2/2
mice, single mutants and WT littermates. Mice were either left
untreated or subjected to i.p injection of MMC (12.5 mg/kg) and
the level of death of B220
+ BM cells was examined three days later
using PI staining. Increased cell death was observed in B220
+ BM
cells from both untreated and MMC treated double mutant mice
compared to control littermates (Figure 3F).
These data indicate that in contrast to p53 inactivation [12], loss
of Chk2 synergizes MMC hypersensitivity of Mus81
Dex3-4/Dex3-4
mice and BM cells.
Increased Mitotic Catastrophe of Mus81
Dex3-4/Dex3-4Chk2
2/2
Cells
Mitotic catastrophe is an abnormal mitosis that triggers the
death of cells with damaged DNA as they enter mitosis [22].
Mitotic catastrophe is also triggered by agents that affect the
stability of microtubules as well as by mitotic failure that results
from impaired cell cycle checkpoints. Chk2, which is importa-
nt for G2/M checkpoint, has been reported to negatively
regulate mitotic catastrophe of DNA damaged cells [23]. As
Mus81
Dex3-4/Dex3-4Chk2
2/2 cells displayed increased levels of
spontaneous cell death and these mutant cells and mice also
displayed elevated MMC-induced cell death, we have examined
whether cell death of Mus81
Dex3-4/Dex3-4Chk2
2/2 cells is triggered
by mitotic catastrophe. Cells undergoing mitotic catastrophe
typically display micronuclei, increased frequency of giant cells,
multilobed nuclei, and nuclear bridging [22].
Untreated Mus81
Dex3-4/Dex3-4Chk2
2/2 primary MEFs stained
with DAPI displayed increased frequency of abnormal giant cells
with multilobed nuclei compared to controls MEFs (P,0.025;
Figure 4A and 4E). Lagging chromosomes were also observed in
untreated Mus81
Dex3-4/Dex3-4Chk2
2/2 MEFs (Figure 4B). The
frequency of untreated double mutant MEFs displaying micronu-
clei was also elevated compared to controls (P,0.018; Figure 4F).
In response to MMC, Mus81
Dex3-4/Dex3-4Chk2
2/2 MEFs displayed
increased frequency of giant cells with multilobed nuclei (P,0.01;
Figure 4G) as well as cells with nuclear bridging (P,0.001;
Figure 4D and 4H). These data indicate increased mitotic
catastrophe of Mus81
Dex3-4/Dex3-4Chk2
2/2 cells.
Loss or reduction of the expression of survivin [24], an inhibitor
of apoptosis protein (IAP), has been shown to lead to cell death by
mitotic catastrophe [25]. We have therefore performed Western
blot analyses to examine the levels of survivin in untreated or 18 hr
and 24 hr post-MMC treatment of LPS activated B-cells from
Mus81
Dex3-4/Dex3-4Chk2
2/2 mice, single mutants and WT controls.
We observed a lower level of survivin in MMC treated
Mus81
Dex3-4/Dex3-4Chk2
2/2 B-cells compared to single mutants
and WT controls (Figure S8). We propose that decreased survivin
level in Mus81
Dex3-4/Dex3-4Chk2
2/2 cells could contribute to their
mitotic catastrophe.
Increased mitotic catastrophe would trigger cell death of
Mus81
Dex3-4/Dex3-4Chk2
2/2 cells and therefore is likely to contrib-
ute to the impaired homeostasis of BM cells, thymocytes and
splenocytes in double mutant mice.
Impaired of Activation of p53 and Defective G2/M
Checkpoint in Mus81
Dex3-4/Dex3-4Chk2
2/2 Cells
p53 plays a central role in DNA damage responses and its
phosphorylation by Chk2 on Serine 20 is important for its stability
and activation [26]. Therefore, we examined the level of p53
expression and activation in double mutants and control B-cells
from the four genotypes. While LPS activated double mutant B-
cells displayed increased cell death levels (Figure 5A), the basal
level of p53 in these activated B-cells remained similarly low
compared to single mutants and WT B-cells (Figure 5B). MMC
treatment of WT and Mus81
Dex3-4/Dex3-4 activated B-cells increased
p53 expression levels (Figure 5B). However, double mutant and
Chk2
2/2 cells failed to increase their level of p53 in response to
MMC treatment (Figure 5B). In accordance with the low level of
p53 in untreated and MMC treated double mutant cells, the level
of Serine 15-p53 (a substrate for ATM), and the levels of Bax and
p21 (p53 downstream targets) were low to undetectable in double
mutant cells under untreated conditions and were not induced in
response to MMC (Figure 5C). In contrast, the expression levels of
Serine 15-p53, Bax and p21 in Mus81
Dex3-4/Dex3-4 and WT cells
were significantly increased in response to MMC (Figure 5C).
These data indicate that despite the lack of p53 activation in
double mutant B-cells, these cells displayed elevated level of
spontaneous and MMC-induced death, supporting that this death
is p53- independent. Consistent with these data, mitotic catastro-
phe has been shown to take place in a p53-independent manner
[27].
Chk2 is required for the enforcement of the G2/M cell cycle
checkpoint following DNA damage [16,18]. It has been shown
that loss of Chk2 expression or inhibition of its kinase activity
sensitizes cells to death during mitosis [23]. Therefore, we have
examined G2/M cell cycle checkpoint in untreated and MMC-
treated double mutant and control activated B-cells (Figure 5D).
While the fraction of mitotic cells (positive for phospho-Histone
H3) was reduced 18 hr and 24 hr post MMC treatment in WT
and Mus81
Dex3-4/Dex3-4 B-cells, both Chk2
2/2 and Mus81
Dex3-4/Dex3-4
Chk2
2/2 B-cells failed to activate G2/M checkpoint in response to
MMC treatment as indicated by their increased fraction of
phospho-Histone H3 positive cells compared to untreated controls
(Figure 5D).
These data indicate that despite MMC-induced DNA damage,
double mutant cells are allowed to enter mitosis, due to their
impaired G2/M checkpoint, therefore resulting in mitotic
catastrophe and cell death.
Effect of Chk2 Inactivation on Genomic Instability of
Mus81
Dex3-4/Dex3-4 Cells
Mus81
Dex3-4/Dex3-4 mice display elevated levels of genomic
instability [11], likely due to their defective repair of stalled RFs
[28]. Genomic instability was also increased in Mus81
Dex9-12/Dex9-12
MEFs expressing the oncoprotein E6[10] and in Mus81
Dex1-10/Dex1-10
ES cells treated with Hydoxyurea [28]. In addition, inactivation of
MUS81 by gene targeting in the human colon cancer cell line
HCT116 also increased the level of genomic instability of these cells
[13].
While Chk2 inactivation resulted in increased genomic
instability of Brca1
2/2 cells, it did not for Nbs1
2/2 or Mre11
2/2
cells [29,30]. To determine the effect of Chk2 inactivation on
the increased spontaneous genomic instability associated with
Mus81
Dex3-4/Dex3-4 mutation [11], we examined metaphase spreads
of activated B-cells from the different genotypes. These analyses
indicated elevated level of spontaneous genomic instability of
Mus81
Dex3-4/Dex3-4 B-cells while Chk2
2/2 B-cells exhibited only a
slightly increased level of spontaneous genomic instability
(Figure 6A and 6B; Table S3). Remarkably, while inactivation
of p53 exacerbated spontaneous genomic instability of
Mus81
Dex3-4/Dex3-4 cells [12], inactivation of Chk2 in these cells
significantly suppressed their spontaneous genomic instability.
Multicolor fluorescence in situ hybridization (mFISH) also failed to
detect any interchromosomal aberrations like translocations in
Mus81
Dex3-4/Dex3-4Chk2
2/2 cells and their controls (Figure 6C).
These data suggest that either Chk2 inactivation decreases the
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2/2 cells that carry genomic instability, or
alternatively that it prevents genomic instability from occurring in
Mus81 mutants. However, the latter is inconsistent with the drastic
increased genomic instability of MMC-treated double mutant B-
cells compared to Mus81
Dex3-4/Dex3-4 controls (Figure 6A and 6B;
Table S3).
To examine whether the reduced level of spontaneous genomic
instability of Mus81
Dex3-4/Dex3-4 B-cells in Chk2 null background
was restricted to these cells or could be observed in other cell types,
we have examined metaphase spreads from activated T-cells and
primary MEFs from the four genotypes. Similar to B-cells,
Mus81
Dex3-4/Dex3-4Chk2
2/2 T-cells (Table S4) and MEFs (Table
S5) displayed reduced levels of spontaneous genomic instability
compared to Mus81
Dex3-4/Dex3-4 controls. In addition, in resp-
onse to MMC treatment, similar to double mutant-B-cells,
Mus81
Dex3-4/Dex3-4Chk2
2/2 T-cells exhibited elevated levels of
genomic instability compared to their Mus81
Dex3-4/Dex3-4 controls
(Table S4).
The increased genomic instability of MMC treated
Mus81
Dex3-4/Dex3-4Chk2
2/2 cells compared to Mus81
Dex3-4/Dex3-4
cells is consistent with their failure to activate G2/M checkpoint.
Despite their DNA damage, these double mutant cells enter
mitosis where they suffer mitotic catastrophe. Under normal
conditions, mitotic catastrophe could serve to trigger cell death
and eliminate Mus81
Dex3-4/Dex3-4Chk2
2/2 cells carrying damaged
DNA. Therefore, increased mitotic catastrophe of Mus81
Dex3-4/Dex3-4
Chk2
2/2 cells could allow to suppress spontaneous genomic
instability. Under chronic conditions of DNA damage (presence of
MMC), Mus81
Dex3-4/Dex3-4Chk2
2/2 cells accumulate excessive DNA
damage due to theirimpaired G2/M checkpoint (Chk2 inactivation)
and defective DNA damage repair (Mus81 inactivation), thus
leading to accumulation of chromosomal aberrations. However,
these cells are ultimately eliminated as indicated by the increased
MMC sensitivity of Mus81
Dex3-4/Dex3-4Chk2
2/2 mice (Figure 3E),
increased mitotic catastrophe (Figure 4) and cell death (Figure 3F) of
MMC double mutant treated cells.
Inactivation of Chk2 Suppresses Tumorigenesis of
Mus81
Dex3-4/Dex3-4 Mutants
CHK2 is mutated in certain human familial cancers and in a
number of other tumors [18]. Tumorigenesis was also observed in
a mouse model for CHK2 del1100C, a mutation associated with
increased cancer risk in humans [31]. In addition, inactivation of
Chk2 increased cancer risk of Brca1, Nbs1 and Mre11 mutant mice
[30]. Stracker et al. demonstrated that inactivation of Chk2 in
DNA-PKcs deficient background did not predispose these mice for
cancer, and proposed that Chk2 suppresses the oncogenic
potential of DNA damage arising in the S and G2 but not G1
phases of the cell cycle [30].
Mus81
Dex3-4/Dex3-4 mice have increased risk for cancer [11], and
this cancer risk is further exacerbated in p53
2/2 background [12].
In order to address the effect of Chk2 inactivation on tumorig-
enesis of Mus81 mutant mice, cohorts of Mus81
Dex3-4/Dex3-4
Chk2
2/2, Mus81
Dex3-4/Dex3-4Chk2
+/2, Mus81
Dex3-4/Dex3-4, Chk2
2/2
and WT mice were monitored for survival and tumorigenesis for a
period of one year (Figure 7A). As expected, tumors were not
observed in WT and Chk2
2/2 mice in accordance with our
previous studies [11,12], Mus81
Dex3-4/Dex3-4 mice displayed in-
creased risk for tumors and only 55% (11/20) of the monitored
Mus81
Dex3-4/Dex3-4 mice were viable and tumor-free at the end of
one year. Remarkably, loss of Chk2 dramatically rescued tumor
susceptibility of Mus81
Dex3-4/Dex3-4 mice as 90% of double mutant
mice (18/20) were viable and tumor-free at the end of one year
(P=0.02; double mutants versus Mus81
Dex3-4/Dex3-4 mice). The two
double mutant mice that did not survive the one year observation
period died of infection. Mus81
2/2 mice in Chk2 null background
were however not fully protected from tumorigenesis as three
double mutant mice (6%) developed tumors past 15 months of age.
Histological analyses demonstrated that tumors developed in
Mus81
Dex3-4/Dex3-4 mice (1 year old or younger) were B-cell
lymphoma (84%), large T-cell lymphoma (8%) and osteocarci-
noma (8%). Histological examination of the three tumors that
developed in Mus81
Dex3-4/Dex3-4Chk2
2/2 mice past 15 months of
age, indicated that one of the tumors was a sarcoma while the two
others were B-cell lymphomas.
The remarkable mitigation of tumorigenesis of Mus81
Dex3-4/Dex3-4
mice by Chk2 inactivation parallels their reduced level of
spontaneous genomic instability, failure of G2/M checkpoint and
increased mitotic catastrophe. Our finding is consistent with a
beneficial effect of CHK2 inhibition on tumor responses to
genotoxic chemotherapeutic drugs [18].
Chk2 Inactivation Suppresses Oncogenic Transformation
of Mus81
Dex3-4/Dex3-4 Cells
Dysregulation of oncogenes, similar to tumor suppressors, plays
critical roles in human cancer. Chk2 is activated by oncogenes
such as Ras, and is important for mediating oncogene-induced
senescence, a safeguard against cancer development [32]. In
addition, Chk2 inactivation has been shown to promote oncogenic
transformation [19].
We therefore investigated the effect of Chk2 inactivation on
transformation of Mus81
Dex3-4/Dex3-4 cells and examined oncogenic
transformation of double mutant primary MEFs, single mutants and
WT controls. Cells were infected with a retrovirus expressing E1A
and Ras and transformed colonies were counted three weeks later
(Figure 7B and 7C). Consistent with previous studies [19], the
number of E1A-Ras transformed colonies formed by Chk2
2/2 MEFs
w a se l e v a t e dc o m p a r e dt oWT controls (P,0.05). Strikingly, while
Mus81
Dex3-4/Dex3-4 MEFs were able to form E1A-Ras transformed
colonies at a similar frequency compared to WT MEFs (P=0.36),
no E1A-Ras transformed colonies were obtained from
Mus81
Dex3-4/Dex3-4Chk2
2/2MEFs inthree independent experiments.
To confirm that the lack of transformation of Mus81
Dex3-4/Dex3-4
Chk2
2/2 MEFs is due to the loss of Mus81 and Chk2 and not due
to the inability of these MEFs to be infected with pBabe E1A-
HRasV12 retrovirus, MEFs from the four genotypes were infected
with this retrovirus and genomic DNA of these cells was prepared
7 days post puromycin selection and PCR analysis was performed
to assess the presence of E1A-HRasV12 in the extracted genomic
DNA. These analyses demonstrated that despite integration of
Figure 4. Loss of Chk2 Triggers Mitotic Catastrophe of Mus81
2/2 Cells. (A) Representative giant Mus81
Dex3-4/Dex3-4Chk2
2/2 MEFs with
multilobed nuclei (arrow head). (B) Representative abnormal metaphase with lagging chromosomes (star) in Mus81
Dex3-4/Dex3-4Chk2
2/2 MEFs. (C)
Representative MMC treated Mus81
Dex3-4/Dex3-4Chk2
2/2 MEFs showing a giant cell with multilobed nuclei and micronuclei (arrowhead). (D)
Representative MMC treated Mus81
Dex3-4/Dex3-4Chk2
2/2 MEFs showing nuclear bridging (arrow). (E) Percentage of giant cells with multilobed nuclei in
untreated WT, Mus81
Dex3-4/Dex3-4, Chk2
2/2, Mus81
Dex3-4/Dex3-4Chk2
2/2 primary MEFs. (F) Percentage of untreated primary MEFs with micronuclei. (G)
Percentage of giant cells with multilobed nuclei in primary MEFs post 24 hr of MMC treatment. (H) Percentage of MMC treated primary MEFs with
nuclear bridging. *: P,0.02. UT: untreated. Mus81
2/2: Mus81
Dex3-4/Dex3-4.
doi:10.1371/journal.pgen.1001385.g004
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Dex3-4/Dex3-4Chk2
2/2 MEFs
(Figure 7D), these cells failed to be transformed.
These data demonstrate that similar to the suppression of spont-
aneous tumorigenesis of Mus81
Dex3-4/Dex3-4 mice, Chk2 inactivation
also suppresses oncogenic transformation of Mus81
Dex3-4/Dex3-4
cells.
Collectively our data demonstrate an important role for Chk2 in
maintaining homeostasis of BM cells, thymocytes and splenocytes
deficient for Mus81. Remarkably, inactivation of Chk2 also
reduced spontaneous genomic instability associated with Mus81
mutation, and significantly protected Mus81 mutants from
tumorigenesis and oncogenic transformation. We also report
increased mitotic catastrophe in double mutant cells, likely due to
the inactivation of G2/M checkpoint associated with loss of Chk2
and increased spontaneous DNA damage associated with loss of
Mus81. The phenotypes observed in Mus81
Dex3-4/Dex3-4Chk2
2/2
mice are p53-independent. In contrast to Mus81
Dex3-4/Dex3-4Chk2
2/2
cells, Mus81
Dex3-4/Dex3-4p53
2/2 cells retain proficient G2/M check-
point that prevents their entry to mitosis in the presence of damaged
DNA. Therefore, we propose that G2/M checkpoint failure and
Figure 5. Loss of Chk2 Impairs p53 Activation and G2/M Checkpoint in Mus81
2/2 Cells. (A) The cell death level of activated
Mus81
Dex3-4/Dex3-4Chk2
2/2 B-cells and controls. Data is presented as the mean 6 SD of four independent experiments. * P=0.016. (B) Representative
Western blot analysis of total p53 in LPS activated B-cells untreated (2) or treated with MMC (+). (C) Representative Western blot analysis performed
as indicated in (B) shows the expression level of Serine 15-p53 (p-p53 ser 15), Bax, p21 and b-actin. (D) Representative FACS analysis of LPS activated
B-cells either untreated or treated for 18 hr or 24 hr with MMC. Percentage of mitotic cells (p-Histone H3
+) is indicated. Mus81
2/2: Mus81
Dex3-4/Dex3-4.
doi:10.1371/journal.pgen.1001385.g005
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reduced spontaneous genomic instability, tumorigenesis and onco-
genic transformation.
Our data provide in vivo evidence that inhibition of Chk2 can have
remarkable inhibitory effects on tumorigenesis. While pharmacolog-
ical inhibitors of CHK2 are being considered for cancer therapy [18],
our data suggest that the therapeutic effect of such inhibitors is likely
to depend on the genetic background of the tumors. Namely, while
Chk2 inactivation promotes tumorigenesis of Brca1, Nbs1 and Mre11
mutant strains, it remarkably suppresses cancer in Mus81
Dex3-4/Dex3-4
mutant background. Our preclinical data highly support the potential
therapeutic value for CHK2 or MUS81 inhibitors for cancer patients
with MUS81 or CHK2 mutations, respectively.
Materials and Methods
Mice
Mus81
Dex3-4/Dex3-4Chk2
2/2 mice were obtained by crossing
Mus81 [11] and Chk2 [33] mutant mice. Mice were in a mixed
129/J 6 C57BL/6 genetic background and were genotyped by
PCR (conditions available upon request).
Flow Cytometry
BM, thymus and spleen cells from 6–8 week-old mice were
stained with antibodies (Pharmingen) against B220, CD43, IgM,
IgD, Thy1.2,TCR, CD4, CD8, CD44, CD25 and TCRVb (4,5.1–
5.2, and 17a). Fluorescence-activated cell sorting (FACS) analyses
were performed using a FACS Calibur (Becton Dickinson).
Cell Cycle Analysis
Peripheral T-cells stimulated with anti-CD3 and IL-2 (50 U/mL)
for 48 h, weretreatedwith 0.5 mg/mlMMC (Sigma) for 18 hr. Cells
were washed three times with PBS and cultured for an additional
18 hr. Cells were fixed in 70% ethanol, and DNA was stained with
5 mg/mL of PI (Sigma). Cells at the G1, S, and G2/M phases of the
cell cycle were determined using FLOWJO analysis software.
Phospho-Histone H3 Staining
Peripheral B-cells activated with LPS (10 mg/ml) for 48 hr, were
treated with 0.1 mg/ml of MMC (Calbiochem) for 18 hr. Cells
fixed and permeabilized with ice cold methanol were stained with
anti-phospho Histone-H3 ser10 FITC (Cell Signaling). Cells were
analysed using FACS Calibur (Becton Dickinson) and results were
analysed using FLOWJO analysis software.
CFSE Staining
Peripheral T-cells were stained with 5 mM CFSE and then
activated for two days with plate bound anti-CD3 in the presence
of IL-2. Untreated and 0.1 mg/ml MMC treated cells were grown
for an additional 72 hr and analyzed by flow cytometry.
MEFs and Retrovirus Infection
Primary MEFs (3610
5) were cultured in DMEM plus 10% FCS
in the presence of pBabe E1A-HRasV12 retrovirus and 8 mg/ml of
polybrene. At day three post-infection, Puromycin selection (2 mg/
ml) was carried out for three weeks. Colonies on the plates were
fixed with ice cold methanol, stained with 0.5% crystal violet and
counted. To confirm that MEFs have integrated E1A-HRasV12,
genomic DNA was prepared from infected cells post 7 days of
puromycin selection. PCR was then performed on MEFs genomic
DNA using specific primers for HRasV12 (F: CGGAATA-
TAAGCTGGTGGTG and R: CGGTATCCAGGATGTC-
CAAC). Eme2 primers (F: ACGGCTTCCCTACCAGCACA
and R: AGTGGCTGCTACTCGGCTTCA) were used as controls
for the PCR.
Chromosomal Aberrations Analysis
LPS (10 mg/ml) activated splenocytes were cultured for 48 hr in
the presence or absence of MMC (40 ng/ml) and metaphase
spreads prepared as previously described [11]. Chromosomal
aberrations were determined for a minimum of 60 metaphase
spreads per cell type. In mFISH, all 21 chromosomes are each
painted in a different color using combinatorial labeling and
mFISH probe kit (MetaSystems) as previously described [34].
T-cells were activated with anti-CD3 (10 mg/mL) + IL2 (50 U/
mL) for 48 hr in the presence or the absence of MMC (40 ng/ml).
Metaphase spreads were prepared as described [11]. Chromo-
somal aberrations were determined for a minimum of 100
metaphase spreads.
Metaphase spreads of primary MEFs were similarly prepared
and chromosomal aberrations were determined for a minimum of
50 metaphase spreads.
Percent aberrations are calculated as aberrations per metaphase
then percentages are determined. Breaks/Fragments include
chromosome breaks, chromatid breaks, and chromosome frag-
ments. Structural aberrations include chromosome fusions (such as
end to end fusions, Robertsonian fusion like configurations).
Bone Marrow Colony Forming Assay
BM cells (1610
5) seeded on 35 mm dishes in Methocult GF
M3434 media (Stemcell Technologies Inc.) were either left
untreated or treated with MMC (40 ng/ml) and cultured for 12
days prior to counting.
Cell Death Assays
Cell death was assessed using 7AAD, PI or Annexin V-PI
staining and FACS analysis as described [12].
Immunobloting
Activated B-cells treated with 0.1 mg MMC (Sigma) were
harvested and lysed 18 hr post-treatment. Proteins were detected
using the following anti-rabbit antibodies: anti-p53 (FL393, Santa
Cruz), anti-Phospho-p53 Ser-15 (cell signaling),anti-p21 (Santa cruz),
anti-Bax (Santa cruz), anti-Survivin (Novus) and anti-b-actin (Sigma).
Immunostaining
Passage 1 MEFs derived from WT and Mus81
Dex3-4/Dex3-4,
Chk2
2/2, and Mus81
Dex3-4/Dex3-4Chk2
2/2 embryos were seeded
onto coverslips and either left untreated or treated with MMC
(1 mg/ml). 24 hr post treatment, MEFs were fixed with 2%
paraformaldehyde, blocked with antibody dilution buffer and
Figure 6. Effects of Chk2 Inactivation on Genomic Instability of Mus81
2/2 Cells. (A) Representative metaphases of LPS activated
Mus81
Dex3-4/Dex3-4 and Mus81
Dex3-4/Dex3-4Chk2
2/2 B-cells either untreated (UT) or post-MMC treatment (MMC). f: chromosomal fusion, dm: double
minute and br: break. (B) Incidence of total spontaneous (UT, left panel) and MMC-induced chromosomal aberrations (MMC, right panel). Data is
presented as the mean 6 SD of three independent experiments. A minimum of 50 metaphase spreads were analyzed for each genotype,
treatment and experiment. (C) mFISH performed on metaphase spreads from Mus81
Dex3-4/Dex3-4,C h k 2
2/2 and Mus81
Dex3-4/Dex3-4Chk2
2/2 cells. Mus81
2/2:
Mus81
Dex3-4/Dex3-4.
doi:10.1371/journal.pgen.1001385.g006
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Leica) under 100X magnification.
Bone Marrow Transplantation
Bone marrow cells were harvested from the femur of 8 week old
mice. 1610
6 cells were transplanted to 6 week old Rag1
2/2 mice
by tail vein injection. The transplanted mice were scarified and
analysed 8 weeks post-transplantation.
In Vivo Sensitivity to MMC–Induced Damage
Mice (n=10) for each genotype were injected (i.p) with 12.5 mg
MMC/Kg of body mass and observed for two weeks post
Figure 7. Inactivation of Chk2 Suppresses Tumorigenesis and Oncogenic Transformation of Mus81
2/2 Mutants. (A) Kaplan-Meier
analysis percent of the survival for WT (n=20), Mus81
Dex3-4/Dex3-4 (n=20), Chk2
2/2 (n=20), Mus81
Dex3-4/Dex3-4Chk2
+/2 (n=10) and Mus81
Dex3-4/Dex3-4
Chk2
2/2 (n=20) cohort mice monitored for 1 year. Log Rank test statistical analysis of survival curves; * P=0.02. (B and C) WT, Mus81
Dex3-4/Dex3-4,
Chk2
2/2, and Mus81
Dex3-4/Dex3-4Chk2
2/2 primary MEFs were infected with a retrovirus coexpressing E1A and Ras and selected with puromycin.
Three weeks post-infection colonies were counted. (B) Representative pictures of colonies at day 21 post-infection and the number of colonies
counted are shown (C). Data are representative of three independent experiments. * P,0.05. ** No E1A-Ras transformed Mus81
Dex3-4/Dex3-4
Chk2
2/2 colonies were observed in three independent experiments. (D) Representative PCR analysis confirming integration of E1A-HRasV12 in
MEFs infected with E1A-HRasV12I retrovirus for 10 days. HRas specific primers were used. Eme2 primers were used for PCR control. Mus81
2/2:
Mus81
Dex3-4/Dex3-4.
doi:10.1371/journal.pgen.1001385.g007
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the day of sacrifice was counted as day of death.
Statistical Analysis
The two tailed unpaired student’s t test was used for statistical
analysis except for survival curves where Log Rank test was
employed (Prism 5, GraphPad Software).
Ethics Statement
All experiments were performed in compliance with Ontario
Cancer Institute animal care committee guidelines.
Supporting Information
Figure S1 Weight of Mus81
-/-Chk2
-/- Females and Controls. Weight
of 6 to 8 week old or 4 to 8 month old WT, Mus81
Dex3-4/Dex3-4,
Chk2
-/-,a n dMus81
Dex3-4/Dex3-4Chk2
-/- females. No difference was
observed. Mus81
-/-: Mus81
Dex3-4/Dex3-4.
Found at: doi:10.1371/journal.pgen.1001385.s001 (0.55 MB TIF)
Figure S2 Effects of Chk2 Inactivation on Homeostasis of
Lymphocytes from Mus81
-/- Mice. (A) Ratio of Thy1.2
+ and
B220
+ splenocytes from the 6 to 8 week old indicated mice. At
least four independent experiments using one mouse per group
were performed. (B) Total number of macrophages in spleen of the
indicated mice. (C) Total number of CD4
2CD8
2 thymocytes in
the indicated mice. (D) Total number of CD4
+CD8
+ thymocytes
in the indicated mice. (E) Total number of CD4
+ thymocytes in
the indicated mice. (F) Total number of CD8
+ thymocytes in
the indicated mice. **: P = 0.0002. *: P=0.0001. At least
four independent experiments using one mouse per group
were performed. Bar graphs show means 6 SEM. Mus81
-/-:
Mus81
Dex3-4/Dex3-4.
Found at: doi:10.1371/journal.pgen.1001385.s002 (1.08 MB TIF)
Figure S3 Effects of Chk2 Inactivation on Death of Lympho-
cytes from Mus81
-/- Mice. (A) Percentage of cell death of Naı ¨ve
CD4
+ T-cells from Spleen of Mus81
Dex3-4/Dex3-4Chk2
-/- Mice. (B)
Percentage of cell death of Naı ¨ve CD8
+ T-cells from Spleen of
Mus81
Dex3-4/Dex3-4Chk2
-/- Mice. (C) Representative FACS analysis
of cell death performed on untreated (UT) or LPS activated
B-cells (48hr) from the indicated mice using PI assay. Numbers
indicates the percent of dead cells. At least four independent
experiments using one mouse per group were performed.
Bar graphs show means 6 SEM. *: P,0.04. Mus81
-/-:
Mus81
Dex3-4/Dex3-4.
Found at: doi:10.1371/journal.pgen.1001385.s003 (4.35 MB TIF)
Figure S4 Mus81
-/-Chk2
-/- Mice Display Normal TCR
Expression. (A) Representative FACS histograms of pan
TCRVb expression in thymocytes from WT, Mus81
Dex3-4/
Dex3-4,C h k 2
-/- and Mus81
Dex3-4/Dex3-4Chk2
-/-mice. Bars indicate
the TCRVb
High positive cells. (B) Percentage of the TCRVb
(4, 5.1-5.2 and 17a) positive thymocytes. Numbers indicates
the percent of TCRVb positive cells. At least five independent
experiments using one mouse per group were performed. Bar
graphs show means 6 SEM. (C) Representative FACS
histograms of pan TCRVb expression in splenocytes
from WT, Mus81
Dex3-4/Dex3-4,C h k 2
-/- and Mus81
Dex3-4/Dex3-4
Chk2
-/-mice. Bars indicate the TCRVb positive cells. Mus81
-/-:
Mus81
Dex3-4/Dex3-4.
Found at: doi:10.1371/journal.pgen.1001385.s004 (1.90 MB TIF)
Figure S5 Defective Homeostasis of the B-Cell Lineage in the
Mus81
-/-Chk2
-/- Mice. Representative FACS analysis of anti-B220
and anti-IgM staining of the B220
+CD43
2 gated BM cells from
WT, Mus81
Dex3-4/Dex3-4, Chk2
-/-, and Mus81
Dex3-4/Dex3-4Chk2
-/- mice
(top). Representative FACS analysis of anti-IgD and anti-IgM
staining of the B220
+ gated BM cells from WT, Mus81
Dex3-4/Dex3-4,
Chk2
-/-, and Mus81
Dex3-4/Dex3-4Chk2
-/- mice (bottom). At least four
independent experiments using one mouse per group were
performed. Mus81
-/-: Mus81
Dex3-4/Dex3-4.
Found at: doi:10.1371/journal.pgen.1001385.s005 (2.77 MB TIF)
Figure S6 The Developmental Defect of Mus81
-/- Chk2
-/-
Lymphocytes Is Cell Autonomous. (A) Representative FACS
analysis of anti-B220 and anti-CD43 staining of the BM cells
from Rag1
-/-mice reconstituted with BM cells from WT,
Mus81
Dex3-4/Dex3-4, Chk2
-/-,o rMus81
Dex3-4/Dex3-4Chk2
-/- mice.
(B) Absolute cell number of recirculating (CD43
2B220
high)B M
cells from Rag1
-/- reconstituted mice as in (A). (C) Absolute
number of total, CD4
+ and CD8
+ thymocytes of Rag1
-/-
reconstituted mice as in (A). (D) Absolute number of total
splenocytes, B-cells, T- cells, CD4
+ T-cells and CD8
+ T-cells from
Rag1
-/- reconstituted mice as in (A). Numbers of cells are indicated.
At least four independent experiments using one mouse per group
were performed. Bar graphs show means 6 SEM. *: P,0.05.
Mus81
-/-: Mus81
Dex3-4/Dex3-4.
Found at: doi:10.1371/journal.pgen.1001385.s006 (5.17 MB TIF)
Figure S7 Effect of Chk2 Inactivation on the Proliferation and
DNA Damage Response of Mus81
-/- Lymphocytes. (A) Represen-
tative cell cycle analysis of WT, Mus81
Dex3-4/Dex3-4, Chk2
-/-, and
Mus81
Dex3-4/Dex3-4Chk2
-/- activated T-cells (anti-CD3 + IL2) 120h
post stimulation. Cells were either untreated (UT) or treated with
0.5 mg/ml MMC for 18hr (MMC). Percentages of cells in G0/G1,
S, and G2/M are shown. (B) Activated (anti-CD3 + IL2) T-cells
from WT, Mus81
Dex3-4/Dex3-4, Chk2
-/-, and Mus81
Dex3-4/Dex3-4
Chk2
-/- mice were exposed to IR (4 Gy) and 12hr later cell death
was examined using FACS analysis 7-AAD. Data presented is
normalized to UT cells and bar graphs show means 6 SEM.
At least three independent experiments using one mouse per
group were performed. ns: not statistically significant. Mus81
-/-:
Mus81
Dex3-4/Dex3-4.
Found at: doi:10.1371/journal.pgen.1001385.s007 (1.03 MB TIF)
Figure S8 Reduced Expression Level of Survivin in MMC
Treated Mus81
-/-Chk2
-/- B-Cells. Western blot analysis of LPS
activated WT, Mus81
Dex3-4/Dex3-4, Chk2
-/-and Mus81
Dex3-4/Dex3-4
Chk2
-/- B-cells either untreated or MMC treated for 18hr and
24hr. The level of expression of survivin and b-actin proteins is
shown. Mus81
-/-: Mus81
Dex3-4/Dex3-4.
Found at: doi:10.1371/journal.pgen.1001385.s008 (0.16 MB TIF)
Table S1 Litter sizes and frequency of double mutants from
interbreeding of Mus81
Dex3-4/Dex3-4Chk2
-/- mice or compound
heterozygotes.
Found at: doi:10.1371/journal.pgen.1001385.s009 (0.04 MB
DOC)
Table S2 Mus81
Dex3-4/Dex3-4Chk2
-/- females were born at the
expected Mendelian ratio.
Found at: doi:10.1371/journal.pgen.1001385.s010 (0.03 MB
DOC)
Table S3 Spontaneous and MMC–induced chromosomal aber-
rations of activated Mus81
Dex3-4/Dex3-4Chk2
-/- B-cells.
Found at: doi:10.1371/journal.pgen.1001385.s011 (0.07 MB
DOC)
Table S4 Spontaneous and MMC–induced chromosomal aber-
rations of activated Mus81
Dex3-4/Dex3-4Chk2
-/- T-cells.
Found at: doi:10.1371/journal.pgen.1001385.s012 (0.07 MB
DOC)
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Mus81
Dex3-4/Dex3-4Chk2
-/- primary MEFs.
Found at: doi:10.1371/journal.pgen.1001385.s013 (0.05 MB
DOC)
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